MedTrace Logo

Evaluate the Efficacy and Safety of CTO0307 in Adults With Presbyopia

NCT07723716 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2026-08-12

No results posted yet for this study

Summary

This study was to compare the presbyopia correction effect between the treatment group and the control group, evaluated by the proportion of patients who achieved an improvement of 3 lines or more in mesopic binocular DCNVA at 3 hours post-dose after 4 weeks of administration of the investigational product.

Conditions

Interventions

DRUG

Pilocarpine Eye drop

Pilocarpine ophthalmic solution, one drop in each eye, once daily, for up to 28 days

DRUG

Vehicle (Placebo solution)

Vehicle, one drop in each eye, once daily, for up to 28 days.

Sponsors & Collaborators

  • Taejoon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2025-09-25
Completion
2025-09-25

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07723716 on ClinicalTrials.gov